A Randomized Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Subjects With Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma
A Randomized Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Subjects With Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma
The main purpose of this study is to compare how long subjects with esophageal cancer live overall or live without disease progression after receiving nivolumab and ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin
Inclusion Criteria:
Exclusion Criteria
Other protocol defined inclusion/exclusion criteria apply
Neptune City, New Jersey 07753, United States
Buenos Aires, Buenos Aires 1417, Argentina
Capital Federal, Buenos Aires 1264, Argentina
Hirosaki-shi, Aomori 0368563, Japan
Kashiwa-shi, Chiba 2778577, Japan
Akashi-shi, Hyōgo 6738558, Japan
Kawasaki-shi, Kanagawa 216-8511, Japan
Sagamihara-shi, Kanagawa 2520375, Japan
Kurashiki-shi, Okayama-ken 7010192, Japan
Hidaka-shi, Saitama 3501298, Japan
Kitaadachi-gun, Saitama 3620806, Japan
Sunto-gun, Shizuoka 411-8777, Japan
Shimotsuga-gun, Tochigi 321-0293, Japan
Bunkyo-ku, Tokyo 1138519, Japan
Bunkyo-ku, Tokyo 1138677, Japan
Chuo-ku, Tokyo 1040045, Japan
Chuo-ku, Tokyo 1048560, Japan
Koto-ku, Tokyo 1358550, Japan
Minato-ku, Tokyo 1058470, Japan
Shinagawa-ku, Tokyo 142-8666, Japan
Shinjuku-Ku, Tokyo 1608582, Japan
Shinjuku-ku, Tokyo 1628666, Japan
Ube-shi, Yamaguchi 7558505, Japan
Changhua County, Changhua 50006, Taiwan
Kaohsiung County, 0, Taiwan
Edrine, 22010, Turkey (Türkiye)
Surrey, SM2 5PT, United Kingdom